Interview with Laura Vivian, CEO of TrilliumBio
 Laura Vivian |
 Caitlin Dolegowski |
Caitlin Dolegowski (CD): Could you introduce TrilliumBiO and share your core focus areas in life sciences?
Laura Vivian (LV): TrilliumBiO is a biomarker discovery company specializing in the development and commercialization of novel diagnostic tests to translate scientific discoveries into real-world clinical impact.
The company has launched over 100 assays, collaborates with partners domestically and internationally, and processes over 500,000 samples annually through a multi-accredited, CLIA-certified laboratory. We work with industry innovators in biotech and pharma, as well as academic medical centers, foundations, and patient advocacy groups. Headquartered in Maryland, just outside Washington, D.C., we operate within the nation’s third-largest biopharma hub. Our multidisciplinary leadership team brings decades of experience delivering value to patients and partners.
Our core focus is expanding access to critical areas of testing that align with emerging therapeutics and scaling diagnostic solutions that support the development and adoption of new treatments.
CD: What types of early-stage companies or technologies are you most interested in meeting at RESI?
LV: First, we are excited to be able to sponsor RESI JPM 2026 and be part of this great community. Thank you for having us.
We believe we are ideally positioned at the intersection of the life sciences ecosystem to create enormous value for our partners. We’re especially interested in engaging with companies advancing novel therapeutics and diagnostics, investors seeking biomarker and clinical diagnostic expertise for their portfolio companies, and organizations with technologies to in-license or co-develop. Our team brings speed, efficiency, and deep expertise in biomarker strategy and development to help accelerate that journey.
CD: What are some of the key scientific or commercial challenges your team is focusing on solving in the coming year?
LV: At TrilliumBiO, we see ourselves as partners from discovery through delivery, working alongside our clients across R&D, regulatory milestones, and clinical use. That partnership means solving critical barriers that often slow diagnostic development, limit patient access, and delay therapeutic approvals.
We’re not only able to bring new assays to market; we also scale testing volume and accelerate the commercialization of existing assays. Our regulatory expertise and audit readiness gives partners confidence that FDA submissions will succeed, ensuring progress isn’t stalled by compliance hurdles.
Education is foundational to our work, strengthening disease awareness among both patients and providers. With the support of more than 15,000 in our physician network, we make sure that every test result is clinically meaningful and actionable.
CD: Is there anything you’d like the RESI community to know about TrilliumBiO’s mission or upcoming milestones?
LV: We recently announced a strategic partnership with Oncobit, an international leader in precision oncology, to bring advanced monitoring solutions for uveal melanoma, including molecular residual disease (MRD) testing, to the U.S. We’re also preparing awareness initiatives around rare diseases like lymphangioleiomyomatosis (LAM), supported by our VEGF-D assay, and blood-based biomarkers that enable earlier detection of Alzheimer’s disease. Our mission is to advance diagnostics that make a meaningful difference in patient care.
The RESI community should stay tuned, as we’ll be sharing more about these milestones and others soon.
CD: Are there any recent accomplishments that you want us to highlight? (Awards, Grants, FDA Approvals, Social Corporate Responsibility programs, etc.)
LV: We were honored to be named a finalist for the Emerging Life Sciences Company of the Year at the 2025 ICON Awards presented by the Maryland Tech Council, recognizing innovation and impact in the state of Maryland’s life sciences sector. Building on that momentum, we secured FDA approval for a rare disease direct to consumer test within just six months, a milestone that reflects our ability to rapidly translate discovery into patient-ready diagnostics. Alongside these achievements, we continue to strengthen partnerships with patient advocacy groups, ensuring that our breakthroughs are paired with meaningful support for the communities we serve.
Next Phase Newsletter 